Premium
Adverse symptoms during short‐term use of ulipristal acetate in women with uterine myomas and/or adenomyosis
Author(s) -
Hong Yeon Hee,
Han Soo Jin,
Lee Dayong,
Kim Seul Ki,
Jee Byung Chul
Publication year - 2019
Publication title -
journal of obstetrics and gynaecology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 1341-8076
DOI - 10.1111/jog.13917
Subject(s) - medicine , ulipristal acetate , adverse effect , adenomyosis , discontinuation , amenorrhea , abdominal pain , breast pain , menstruation , obstetrics , metrorrhagia , gynecology , endometriosis , pregnancy , family planning , breast cancer , population , biology , environmental health , cancer , research methodology , genetics
Aim To evaluate various adverse symptoms during short‐term use of ulipristal acetate in women with uterine myomas ( n = 90), adenomyosis ( n = 3) or both ( n = 7). Methods One hundred premenopausal women who received ulipristal acetate for 4–12 weeks during 2016 to 2017 were selected. The medical records were reviewed and the following information was collected; adverse symptoms during medication, presence of menorrhagia or menstrual cramps, blood hemoglobin and liver function test. Adverse symptoms were recorded in the medical records as a checklist form including 76 specific progestin‐related symptoms. Results Overall, the most frequent adverse symptom was amenorrhea (43%), followed by weight gain (29%), fatigue (27%), abdominal discomfort (21%), decreased menstrual flow (19%) and dizziness (18%). In 89 symptomatic women (with heavy menstrual bleeding and/or menstrual cramping pain and/or anemia), the most frequent adverse symptom was weight gain (27%) and fatigue (27%), followed by abdominal discomfort (21%), dry eye (18%), facial flushing (17%), dizziness (17%), headache (17%) and increased vaginal discharge (15%). Fourteen women stopped the medication due to unwanted adverse symptoms. Of this discontinuation group, major complaint was fatigue (50%), followed by weight gain (36%) and breast discomfort (35.7%). Conclusion Adverse symptoms were common and discontinuation rate was somewhat higher during short‐term course of ulipristal acetate. Information about incidence of various adverse symptoms should be given to women who willing to take ulipristal acetate.